PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.50
Negative P/E while Healthcare median is -1.73. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
4.24
P/B exceeding 1.5x Healthcare median of 1.95. Jim Chanos would check for potential asset write-down risks.
-16.03
Negative FCF while Healthcare median P/FCF is -8.54. Seth Klarman would investigate cash flow improvement potential.
-16.11
Negative operating cash flow while Healthcare median P/OCF is -6.40. Seth Klarman would investigate operational improvement potential.
4.24
Fair value ratio exceeding 1.5x Healthcare median of 1.98. Jim Chanos would check for valuation bubble risks.
-4.55%
Negative earnings while Healthcare median yield is -2.16%. Seth Klarman would investigate path to profitability.
-6.24%
Negative FCF while Healthcare median yield is -1.98%. Seth Klarman would investigate cash flow improvement potential.